Earkart Limited is a hearing-care company built on a single, patented invention: a portable diagnostic tablet called OMNI that lets one audiologist test and fit hearing aids for patients anywhere in the world, without ever being in the same room. The company was founded in 2021 by Rohit Misra, who spent 15 years as Managing Director of a top global hearing-aid firm watching the same problem go unsolved - roughly 60% of India had no access to an audiologist, and the country still has only about one audiologist for every 187,000 people. That recurring insight - that the bottleneck is not the hearing aid but the professional who prescribes it - explains everything Earkart does: it compresses an entire audiology clinic into an 11-inch tablet, places it inside existing doctors’ practices, and sells its own affordable hearing aids through that network, effectively turning a chronic shortage of specialists into a scalable distribution channel. # Business segments A single integrated business - hearing diagnostics and hearing-aid sales - delivered through two customer channels, government and private, both powered by the same remote-diagnostic platform and the same in-house manufactured devices. ## 1. Remote-enabled hearing care: the clinic-in-a-tablet that makes the sale possible **The OMNI device is the business’s engine - it performs every key hearing test remotely, so a patient in a town with no audiologist can be diagnosed and fitted with a hearing aid by a professional sitting hundreds of miles away.** - **One audiologist, five clinics** - OMNI is a portable, rechargeable unit built around an 11-inch tablet that performs video otoscopy, air and bone conduction audiometry, tympanometry, newborn hearing screening, and speech audiometry, all controlled remotely by a qualified audiologist at a command centre. Because the device handles the full diagnostic stack, a single audiologist can manage up to five clinic locations at once, bypassing the chronic shortage of professionals entirely. - **Programs any brand, not just its own** - the platform can remotely fit and program hearing aids from all manufacturers, which positions OMNI as an industry-wide utility rather than a closed ecosystem tied to Earkart’s devices. That openness is what lets the company say “I’ll sell for everyone” - if a patient wants a competitor’s brand, Earkart can source and fit it through the same clinic. - **Protected by a patent** - the technology is covered by a granted Indian patent for a “Smart Sound Treatment and Diagnosis System,” and as of early 2026 management stated it had no global or domestic competition. The OMNI hardware itself is outsourced to a contract manufacturer, so Earkart’s intellectual property lies in the system and software, not the box. - **Built for places with unreliable power** - the device runs on an 8-hour Li-ion battery and fits inside a small sound-treated room of roughly 6×6 feet, which means it works in clinics across Tier 2 and Tier 3 cities where continuous electricity is not guaranteed. ## 2. Shop-in-Shop clinics: the physical front door in the doctor’s office **Earkart places a sound-treated OMNI booth inside an existing ENT or eye clinic, trains a clinic assistant to operate it, and splits the diagnostic and device revenue with the doctor - turning thousands of independent practices into hearing-care outlets.** - **Piggybacks on the ENT footprint** - India has roughly 16,000 practising ENT doctors but only about 6,500-7,500 audiologists, so putting an OMNI inside an ENT clinic instantly creates a hearing-care point where none existed. The company has identified over 2,000 clinics as potential locations and had installed 82 Shop-in-Shop clinics across more than 40 cities by March 2026. - **Two ways the clinic earns** - the doctor collects a consultation-and-audiometry fee that is split with Earkart, and when a hearing aid is sold the clinic bills the patient, keeps a service fee, and Earkart bills the doctor for the device. Per-installation monthly revenue - combining product sales and service fees - was roughly ₹18,000-20,000 as of December 2025. - **No marketing needed in small towns** - in communities of 20,000-40,000 people where no audiologist has ever practised, management notes that patients accept the service immediately when their local ENT doctor begins offering it via OMNI, with no active promotion required. ## 3. Own-brand hearing aids: affordable devices manufactured in-house **Earkart designs and makes its own digital, rechargeable, Bluetooth-enabled hearing aids at its Noida factory, selling them at roughly half the price of comparable multinational products.** - **Four brands across the price spectrum** - the company markets hearing aids under the EQFY, Fame, Radius, and TINY brands, spanning programmable digital models and lower-cost analog devices. On programmable aids, Earkart sells at around ₹35,000 versus roughly ₹70,000 for multinational peers; on analog aids, the large global companies do not compete at all, so Earkart faces very little competition in that segment. - **End-to-end production under one roof** - the Noida facility handles MIC processing, receiver integration, BTE assembly, and in-house PCBA testing, with an annual capacity of approximately 200,000 hearing aids. The factory holds ISO 13485:2016 certification - the top international medical-device quality standard, held by very few Indian hearing-aid manufacturers - plus CDSCO and BIS approvals that are prerequisites for government procurement. - **More than just hearing aids** - the product range extends to assistive devices such as Multi-Sensory Integrated Educational Development Kits for children with disabilities, teaching-learning material kits, and mobility aids like adjustable foldable walkers, which broadens the catalogue for government and institutional buyers. ## 4. Government supply: the mature, high-volume backbone **Earkart supplies hearing aids and related products to central and state government programs through the Government e-Marketplace portal and a long-standing relationship with ALIMCO, a state-owned medical-device company.** - **Certifications unlock the door** - the ISO 13485, CDSCO, and BIS certifications are mandatory for participating in government medical-device tenders, and Earkart’s possession of all three gives it a qualified-supplier status that fewer domestic competitors can match. - **Geographic concentration** - a significant share of revenue from Uttar Pradesh, which accounted for over three-quarters of total revenue in FY26, is driven by government orders, reflecting the state’s large procurement programs. ## 5. Private distribution: the faster-growing channel into small-town India **Through roughly 1,400 dealer partners across 17 to 22 states, Earkart sells hearing aids directly to consumers in Tier 2 and Tier 3 cities - the “low-hanging fruit” where no other hearing-care option exists.** - **Dealers and lead-generation work in parallel** - dealers buy hearing aids from Earkart and sell them onward to local customers and armed-forces personnel, while a separate online lead-generation model sends prospective patients to dealer partners, with Earkart earning a commission per sale. Own direct sales account for upwards of 85-90% of total revenue. - **Targets the unserved** - the private business specifically pursues small towns with populations of 20,000-40,000 where no audiologist practises, because patients there have no alternative and accept the service readily when an ENT doctor equipped with OMNI offers it. - **Recurring revenue beyond the device** - the company also earns service revenue from audiometry diagnostic tests, conversion charges, franchise fees, and consultancy services, creating income streams that are not tied to a one-time product sale. # Group structure and partners **A Delhi-based public company with a newly listed stock, two fresh overseas subsidiaries for the US and UK, and two more Indian subsidiaries on the drawing board - all aimed at extending the OMNI-powered model beyond its home market.** - Earkart Limited is the listed parent, incorporated in 2021, converted to a public company in 2024, and listed on the BSE SME Platform in 2025. It is led by Promoter and Managing Director Rohit Misra, who spent 15 years running Starkey in India, and Promoter and Whole-Time Director Monika Misra, who oversees daily operations and audiology. - Earkart Inc., a wholly-owned subsidiary incorporated in Delaware in January 2026, was set up to operate a compliant remote audiology and hearing-care platform in the United States, partnering with ENT clinics, insurers, pharmacies, and large retailers. - Earkart Health Limited, a UK subsidiary incorporated in June 2026, is 65%-owned by the parent and was established to provide healthcare services and sell healthcare products, though it had no operations as of the filing date. - Two proposed wholly-owned Indian subsidiaries - Earkart Pharmaceuticals Private Limited and Earkart Healthcare Services Private Limited - were approved by the Board in May 2026 but are yet to be incorporated, signalling an intention to expand into pharmaceuticals and broader healthcare services. - The OMNI audiometer is manufactured by an external contract manufacturer, not in-house, while an exclusive partnership with Arphi Electronics and its pan-India distribution network is noted as a future expansion initiative.